The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX) and the PK of RAM as monotherapy in patients (pts) with advanced malignant solid tumors.
Laura Quan Man Chow
Research Funding - ImClone Systems
David C. Smith
Research Funding - ImClone Systems
Antoinette R. Tan
Research Funding - ImClone Systems
Crystal Shereen Denlinger
Consultant or Advisory Role - Lilly
Research Funding - ImClone Systems
Ding Wang
Research Funding - ImClone Systems
Dale Randall Shepard
Research Funding - ImClone Systems
Archana Chaudhary
Employment or Leadership Position - Lilly
Stock Ownership - Lilly (B)
Yong Lin
Employment or Leadership Position - Lilly
Minori Koshiji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly